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Diabetic patients have coagulation abnormalities, in which thrombin plays a key role. 2 
Whereas accumulating evidence suggests that it also contributes to the development of 3 
vascular dysfunction through the activation of protease-activated receptors (PARs). Here 4 
we investigated whether the blockade of thrombin attenuates endothelial dysfunction in 5 
diabetic mice. Induction of diabetes by streptozotocin (STZ) increased the expression of 6 
PAR1, PAR3, and PAR4 in the aorta. STZ-induced diabetic mice showed impairment of 7 
endothelial function, while the administration of dabigatran etexilate, a direct thrombin 8 
inhibitor, significantly attenuated endothelial dysfunction in diabetic mice with no alteration 9 
of metabolic parameters including blood glucose level. Dabigatran did not affect 10 
endothelium-independent vasodilation. Dabigatran decreased the expression of 11 
inflammatory molecules (e.g., MCP-1 and ICAM-1) in the aorta of diabetic mice. Thrombin 12 
increased the expression of these inflammatory molecules and the phosphorylation of IκBα, 13 
and decreased the phosphorylation of eNOSSer1177 in human umbilical endothelial cells 14 
(HUVEC). Thrombin significantly impaired the endothelium-dependent vascular response 15 
of aortic rings obtained from wild-type mice. Inhibition of NF-κB attenuated thrombin-16 
induced inflammatory molecule expression in HUVEC and ameliorated thrombin-induced 17 
endothelial dysfunction in aortic rings.  Dabigatran attenuated the development of 18 
diabetes-induced endothelial dysfunction. Thrombin signaling may serve as a potential 19 
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Ach; acetylcholine 2 
HUVEC; human umbilical endothelial cell 3 
ICAM; intercellular adhesion molecule 4 
MCP; monocyte chemoattractant protein 5 
PAR; protease-activated receptor 6 
qPCR; quantitative RT-PCR 7 
SNP; sodium nitroprusside 8 
STZ; streptozotocin 9 
VCAM; vascular cell adhesion molecule 10 
 11 
  12 
Rahadian A, et al./ VPH_2019_4 
Effects of dabigatran on diabetic endothelial dysfunction 
4 
 
1. Introduction 1 
Atherosclerosis and subsequent cardiovascular disease are critical complications of 2 
diabetes mellitus [1]. Multiple pathophysiological conditions related to diabetes cause 3 
vascular inflammation [2], leading to the development of atherosclerosis [3]. Vascular 4 
inflammation causes endothelial dysfunction, an initiator of atherosclerosis [4]. Endothelial 5 
dysfunction induces the expression of adhesion molecules and chemokines and alters 6 
vascular responses, which stimulate monocyte-endothelial cell interactions, leading to the 7 
development of atherosclerosis [5]. However, the mechanism that causes endothelial 8 
dysfunction in diabetic patients is not fully understood. 9 
 Previous studies have reported that patients with diabetes mellitus have 10 
coagulation abnormalities [6-8]. For example, hyperglycemia in acute coronary syndrome 11 
patients with and without a previous history of diabetes is associated with enhanced local 12 
thrombin generation [9]. These studies suggested that hyperglycemia promotes thrombin 13 
generation, which is associated with cardiovascular complications, in these patients. The 14 
vascular endothelium primarily has protective effects against atherogenesis; however, an 15 
imbalance of coagulation causes endothelial dysfunction, platelet and monocyte adhesion, 16 
and macrophage activation, as well as blood coagulation, all of which are known to promote 17 
atherogenesis [10]. In the coagulation cascade, thrombin plays a key role, whereas 18 
accumulating evidence suggests its contribution to vascular inflammation through 19 
protease-activated receptor (PAR)1, PAR3, and PAR4, a family of seven transmembrane 20 
G-protein-coupled receptors activated by proteolytic cleavage of the amino-terminal 21 
extracellular domain [11, 12]. Previous studies reported that activation of PARs by thrombin 22 
is associated with the pathophysiology of inflammatory diseases including vascular 23 
inflammation [13]. However, few studies have examined the role of thrombin in the 24 
development of diabetes-related endothelial dysfunction. 25 
Dabigatran is an oral anticoagulant that directly inhibits thrombin and is prescribed 26 
for the prevention of thrombotic complications in patients with atrial fibrillation [14-16]. In 27 
addition, recent studies have reported that dabigatran prevented the development of 28 
atherosclerosis in a hypercholesterolemic mouse model [17-19]. The results of these 29 
studies suggested that the inhibition of thrombin by dabigatran is associated with vascular 30 
protection. Therefore, in this study, to address the hypothesis that inhibition of thrombin 31 
signaling by dabigatran attenuates endothelial dysfunction in diabetic mice, we 32 
administered dabigatran to streptozotocin (STZ)-induced diabetic mice and examined 33 
vascular responses. We also performed in vitro studies using endothelial cells and ex vivo 34 
experiments using aortic rings to investigate the underlying mechanisms. The results of our 35 
study suggest that dabigatran attenuates vascular inflammation and endothelial 36 
dysfunction in diabetic mice, and provides a potential therapeutic target for diabetes-37 
related endothelial dysfunction. 38 
 39 
2. Methods 40 
2.1. Animal experiments 41 
Wild-type (C57BL/6J background) mice were purchased from Japan SLC, Inc. STZ (150 42 
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mg/kg) or vehicle (citrate buffer) was injected intraperitoneally into 8-week-old male wild-1 
type mice. From 3 days after injection, mice were fed normal chow supplemented with 10 2 
mg/g dabigatran etexilate (approximately 1800 mg/kg/day), a direct thrombin inhibitor, for 3 
3 weeks. The control group received non-supplemented chow. STZ was purchased from 4 
Sigma-Aldrich. Dabigatran was provided by Boehringer Ingelheim. Mice were maintained 5 
under a 12-h light/dark cycle with free access to chow and water. All experimental 6 
procedures conformed to the guidelines for animal experimentation of Tokushima 7 
University. The protocol was reviewed and approved by our institutional ethics committee. 8 
2.2. Metabolic parameter analyses 9 
At the time of sacrifice, blood was collected from the heart without fasting into EDTA-10 
containing tubes, and plasma was stored at −80°C until required. Plasma total cholesterol, 11 
high-density lipoprotein cholesterol, and triglyceride levels were measured at LSI Medience 12 
Corporation (Japan). 13 
2.3. Vascular reactivity assay 14 
Analysis of vascular reactivity was performed as we described previously [20]. In brief, the 15 
descending thoracic aortas obtained from each group of mice were cut into 2-mm rings and 16 
mounted in organ baths filled with modified Krebs–Henseleit buffer aerated with 95% O2 17 
and 5% CO2 at 37°C. The preparations were attached to a force transducer, and isometric 18 
tension was recorded on a polygraph. The viability of aortic segments was tested with 31.4 19 
mM KCl. Blood vessel integrity was assessed in response to phenylephrine to induce 20 
vasoconstriction followed by vasorelaxation produced by acetylcholine. Vessel rings pre-21 
contracted with phenylephrine, producing submaximal (60% of maximum) contraction. After 22 
the plateau was attained, the rings were exposed to increasing concentrations of 23 
acetylcholine (Ach, 10−9 to 10−4 M) and sodium nitroprusside (SNP; 10−9 to 10−4 M) to obtain 24 
cumulative concentration–response curves. In ex-vivo experiments, aortic segments 25 
prepared from wild-type mice were incubated with 10 nM thrombin (Sigma-Aldrich) in 26 
DMEM containing 2% FBS in the presence or absence of a NF-κB inhibitor, BAY 11-7082 27 
(Sigma-Aldrich), for 4 hours before analyses of vascular reactivity. 28 
2.4. Flow Cytometry Analysis 29 
To investigate effects of dabigatran on endothelial cells, we performed flow cytometry 30 
analysis using the aorta. The aorta was fractionated as described previously [21]. 31 
Fractionated cells were stained with anti-CD31-Alexa488, anti-ICAM-1-PE/Cy7, and anti-32 
VCAM-1-APC antibodies (Biolegend). Data were acquired on FACSVerse (BD Biosciences) 33 
and the percentage of ICAM-1 or VCAM-1 positive endothelial cells were analyzed. 34 
2.5. Cell culture experiment 35 
Human umbilical vein endothelial cells (HUVEC) were purchased from Life Technologies 36 
and cultured in EGM-2 (Lonza). HUVEC (passage 4–6) were treated with 1-100 nM 37 
thrombin in EBM-2 (Lonza) containing 2% FBS for 4 hours in the presence or absence of 38 
BAY 11-7082. To investigate the effect of high glucose condition on thrombin-induced 39 
endothelial activation, HUVEC which were cultured in EBM-2 or in glucose (50 mM)-40 
supplemented EBM-2, both of which containing 2% FBS, were treated with 10 nM thrombin 41 
for 2 hours. 42 
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2.6. Quantitative RT-PCR 1 
Total RNA was extracted from aortic tissue or HUVEC using an illustra RNAspin RNA 2 
Isolation Kit (GE Healthcare). cDNA was synthesized using a QuantiTect Reverse 3 
Transcription kit (Qiagen). Quantitative real-time PCR (qPCR) was performed using Power 4 
SYBR Green PCR Master Mix (Applied Biosystems) on an Mx3000P (Agilent Technologies). 5 
Data are expressed in arbitrary units normalized by β-actin or GAPDH. The sequences of 6 
primers are listed in Table 1. 7 
2.7. Western blotting 8 
Protein lysates were isolated from aortic tissue or HUVEC using RIPA buffer (Wako Pure 9 
Chemical Industries, Ltd.) containing a protease inhibitor cocktail (Takara Bio Inc.) and 10 
phosphatase inhibitors (Roche LifeScience). Proteins were separated by SDS-PAGE and 11 
transferred to polyvinilidine difluoride membranes (Hybond-P; GE Healthcare). The 12 
membranes were blocked in 5% bovine serum albumin for 1 hour at room temperature, 13 
followed by incubation with primary antibody against either phosphorylated eNOSSer1177, 14 
eNOS (BD Biosciences), phosphorylated IκBα, IκBα (Cell Signaling Technology), ICAM-1, 15 
VCAM-1 (abcam), or β-actin (Sigma) at 4°C overnight. After blots were washed in TBS 16 
containing 1% Tween-20, the membranes were incubated in horseradish peroxidase-17 
conjugated secondary antibody (Chemicon) for 1 hour. Expression of β-actin was used as 18 
an internal control to confirm equivalent total protein loading. Antibody distribution was 19 
visualized with ECL-plus reagent (GE Healthcare) using a luminescent image analyzer 20 
(LAS-1000, Fuji Film). 21 
2.8. Statistical analysis 22 
All data are expressed as mean ± SEM. Comparison of parameters between two groups 23 
was performed with unpaired Student’s t-test. Differences between multiple groups were 24 
analyzed by ANOVA followed by Tukey’s post hoc analysis Comparisons of dose–response 25 
curves were made by two-factor repeated-measures ANOVA, followed by Tukey's post hoc 26 
test for comparison between groups. A value of P < 0.05 was considered significant. 27 
 28 
3. Results 29 
3.1. Induction of diabetes promoted expression of PARs in aorta 30 
To investigate the role of thrombin signaling in the development of endothelial dysfunction, 31 
we examined the expression of thrombin receptors in the aorta. Induction of diabetes 32 
significantly promoted thrombin receptor expression (e.g., PAR1, 3, and 4), as shown in 33 
Figure 1. 34 
3.2. Dabigatran ameliorated endothelial dysfunction in diabetic mice 35 
Endothelial dysfunction is an initial step in atherosclerosis. Therefore, to investigate the 36 
effect of dabigatran on endothelial function, we administered dabigatran to STZ-induced 37 
diabetic mice. Endothelium-dependent vasodilation in response to Ach was impaired in 38 
STZ-induced diabetic mice compared with that in the normoglycemic control group (P < 39 
0.001); however, dabigatran administration significantly ameliorated the impairment of 40 
endothelium-dependent vasodilation compared with the non-treated group (P < 0.001) 41 
(Figure 2A). On the other hand, endothelium-independent relaxation in response to SNP 42 
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did not differ between the dabigatran-treated group and non-treated group (Figure 2B). In 1 
addition, induction of diabetes promoted the expression of monocyte chemoattractant 2 
protein (MCP)-1, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion 3 
molecule (VCAM)-1 in the aorta, while dabigatran administration reduced their expression 4 
(Figure 2C-E). Also, the results of flow cytometry analysis demonstrated that dabigatran 5 
significantly reduced ICAM-1-positive endothelial cells and tended to reduce VCAM-1-6 
positive endothelial cells in the aorta of diabetic mice (Figure 2F and G). Administration of 7 
dabigatran did not alter plasma glucose and plasma lipid levels in diabetic mice (Table 2). 8 
3.3. Thrombin stimulated pro-inflammatory activation of endothelial cells 9 
Dabigatran is a specific inhibitor of thrombin. Therefore, we performed in vitro experiments 10 
using HUVEC to examine the effect of thrombin on endothelial cells. Treatment with 11 
thrombin dose-dependently increased the expression of inflammatory molecules such as 12 
MCP-1, ICAM-1, and VCAM-1 in HUVEC (Figure 3A). Increase in VCAM-1 and VCAM-1 13 
expression in HUVEC was also confirmed in the protein level (Figure 3B). Thrombin 14 
significantly attenuated the phosphorylation of eNOS at Ser1177 in HUVEC (P < 0.05). On 15 
the other hand, thrombin increased the phosphorylation of IκBα (P < 0.01), suggesting 16 
activation of the NF-κB pathway in this cell type (Figure 3C). We further examined the 17 
effect of thrombin under high glucose condition. High glucose condition promotes the 18 
expression of ICAM-1 and MCP-1 in thrombin-treated HUVEC, suggesting that high glucose 19 
condition enhances thrombin-induced inflammatory activation of endothelial cells (Figure 20 
3D).  21 
 To investigate the involvement of NF-κB signaling in thrombin-induced pro-22 
inflammatory activation of endothelial cells, we treated HUVEC with thrombin in the 23 
presence of a NF-κB inhibitor, BAY11-7082. BAY11-7082 ameliorated thrombin-induced 24 
expression of inflammatory molecules in this cell type (Figure 4A-C). To confirm the effect 25 
of thrombin on endothelial function, we incubated aortic segments obtained from wild-type 26 
mice with thrombin, and examined the vascular response. Thrombin markedly reduced 27 
endothelium-dependent vascular relaxation, which was blocked by a NF-κB inhibitor, 28 
BAY11-7082 (Figure 4D). However, thrombin did not alter endothelium-independent 29 
vascular relaxation (Figure 4E). 30 
 31 
4. Discussion 32 
Diabetes causes endothelial dysfunction which is an initial step of atherosclerosis [2]. 33 
Previous studies suggested that endothelial dysfunction could be a potential therapeutic 34 
target for the prevention of vascular disease in these patients [22], although effective 35 
prevention is not established. In this study, we examined whether dabigatran, a direct 36 
thrombin inhibitor, attenuates endothelial dysfunction, using a diabetic mouse model. We 37 
found that dabigatran ameliorated the development of endothelial dysfunction and vascular 38 
inflammation in STZ-induced diabetic mice. In vitro experiments using HUVEC 39 
demonstrated that thrombin promotes the expression of inflammatory molecules at least 40 
partially via the NF-κB pathway. Furthermore, incubation with thrombin impaired the 41 
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vascular response to Ach in mouse aortic rings, although a NF-κB inhibitor attenuated this 1 
response. These results suggest that dabigatran attenuates endothelial dysfunction in 2 
diabetic mice by inhibiting vascular inflammation, and that thrombin serves as a potential 3 
therapeutic target for diabetes-related endothelial dysfunction. 4 
 Diabetic patients have increased risk of vascular complications. The vascular 5 
complications associated with atherosclerosis are the most serious manifestations in 6 
patients with diabetes. Although multifactorial in etiology [23], recent studies 7 
demonstrated that a hypercoagulable state in diabetic patients, which results from 8 
enhanced thrombin generation, for example, is associated with atherosclerotic 9 
complications in these patients [6-10]. Thrombin plays a key role in the coagulation 10 
cascade by cleaving fibrinogen to fibrin, while accumulating evidence indicates that 11 
thrombin has direct effects on the endothelium, independent of blood coagulation. 12 
Thrombin increases inflammatory molecule expression, recruitment of inflammatory cells 13 
[24], generation of reactive oxygen species [25], and vascular tone [26] in endothelial 14 
cells, all of which disturb homeostasis of the vasculature, causing vascular inflammation 15 
and deterioration of endothelial cell function. Prolonged incubation with thrombin has also 16 
been reported to inhibit NO synthesis, which has a critical impact on endothelial function 17 
[27]. Considering these pro-inflammatory roles of thrombin in vascular biology, targeting 18 
thrombin signaling may offer a potential therapeutic target.  19 
 Dabigatran is the first oral anticoagulant that directly inhibits thrombin. Dabigatran 20 
prevents stroke and systemic thromboembolic events in patients with atrial fibrillation [14-21 
16]. In addition to these anti-thrombotic effects, together with the increasing evidence of 22 
pro-inflammatory properties of thrombin, the effect of dabigatran on atherogenesis has 23 
attracted much attention. Several studies have demonstrated that dabigatran prevents the 24 
development and destabilization of atherosclerotic plaques in apolipoprotein E-deficient 25 
mice [17-19]. Furthermore, a previous study demonstrated that dabigatran attenuated 26 
endothelial dysfunction in a hyperlipidemic mouse model [17]. However, few studies have 27 
investigated the effect of dabigatran on endothelial function in a diabetic condition. 28 
 In our present study, induction of diabetes impaired the endothelium-dependent 29 
vascular response and increased the expression of inflammatory molecules (e.g., MCP-1 30 
and ICAM-1), all of which were ameliorated by the administration of dabigatran, without an 31 
alteration of blood glucose level. These results suggest that dabigatran attenuates vascular 32 
inflammation and preserves endothelial function. Although the mouse model was different, 33 
our results are in line with previous studies demonstrating anti-inflammatory and 34 
vasoprotective properties of dabigatran. We also found that induction of diabetes increased 35 
the expression of PARs in the aorta. Previous studies have demonstrated that PAR1, 3, 36 
and 4 mediate non-thrombotic effects of thrombin such as vascular regulation [12, 28]. 37 
Especially, a recent study showed that PAR4 plays a pivotal role in vasculopathy in a 38 
diabetic condition [29]. Therefore, promotion of PAR expression might also play roles in 39 
the development of thrombin-induced endothelial dysfunction in diabetic mice. In our in 40 
vitro experiments, thrombin markedly promoted the expression of inflammatory molecules 41 
and reduced the phosphorylation of eNOS. These findings are consistent with previous 42 
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studies [27]. In this study, we further found that high glucose condition enhances thrombin-1 
induced inflammatory activation of endothelial cells in in vitro experiments. Also, thrombin 2 
activates the NF-κB pathway, and an inhibitor of NF-κB suppressed pro-inflammatory 3 
effects of thrombin in endothelial cells. These results suggest the involvement of NF-κB 4 
signaling in the pro-inflammatory properties of thrombin in endothelial cells. Previous 5 
studies demonstrated that thrombin-induced PAR activation promotes NF-κB signaling [30, 6 
31]. NF-κB signaling promotes the expression of inflammatory molecules and oxidative 7 
stress, leading to the deterioration of eNOS function [32, 33]. Thus, our study suggests that 8 
inhibition of thrombin-PAR signaling by dabigatran may provide a therapeutic option for 9 
diabetes-induced endothelial dysfunction. On the other hand, several previous studies 10 
reported vasodilation effect of thrombin [34, 35]. Marked differences in species, vascular 11 
beds, vascular viability, incubation time and dose might explain this discrepant results [26, 12 
34]. In addition, several signaling pathways are suggested for thrombin, however, it is not 13 
fully understood [36, 37]. Therefore, further studies are needed to elucidate the effect of 14 
thrombin on vascular tone. In this study we focused on anti-inflammatory effects of thrombin, 15 
whereas a recent study demonstrated that thrombin inhibition with dabigatran preserves 16 
endothelial barrier integrity, resulting in atheroprotection [38]. In contrast, one recent study 17 
reported that long-term inhibition of thrombin by dabigatran may increase atherosclerotic 18 
and atherothrombotic risk [39]. Further studies are required to reveal the effect and 19 
underlying mechanisms of dabigatran on vascular function.  20 
 Finally, in this study, we used STZ-induced diabetic mice. This is a widely used 21 
mouse model for diabetes, however this model is more representative for type 1 diabetes. 22 
In clinical studies, the effect of coagulation system on vascular complication have been 23 
mainly investigated in type 2 diabetic patients. Therefore, this is one of the important 24 
limitations for our study. 25 
 26 
5. Conclusions 27 
In conclusion, the results of our study indicated that dabigatran attenuated endothelial 28 
dysfunction in diabetic mice. Considering the pro-inflammatory roles of thrombin in vascular 29 
biology and enhanced coagulation in diabetic patients, the inhibition of thrombin signaling 30 
by dabigatran may offer a promising therapeutic option for treating diabetes-related 31 
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Figure legends 1 
Figure 1. Induction of diabetes promoted expression of PARs in aorta. 2 
Induction of diabetes increased the expression of PAR1, PAR3, and PAR4, receptors for 3 
thrombin, in the aorta. (n = 6–7, per group). STZ; streptozotocin. *; P < 0.05 and **; P < 4 
0.01. All values are mean ± SEM. 5 
 6 
Figure 2. Dabigatran ameliorated endothelial dysfunction in diabetic mice. 7 
(A and B) Vascular reactivity to Ach (A) or SNP (B) was determined using aortic segments 8 
isolated from dabigatran- or non-treated diabetic mice and non-diabetic control mice. 9 
Induction of diabetes by STZ injection impaired the endothelium-dependent vascular 10 
response, while dabigatran administration to diabetic mice for 3 weeks ameliorated this 11 
response (P < 0.001). Vasorelaxation in response to SNP did not differ among the three 12 
groups. (n = 9–14, per group). (C-E) The expression of inflammatory molecules was 13 
examined by qPCR using abdominal aorta. Induction of diabetes by STZ injection increased 14 
the expression of MCP-1 (C), ICAM-1 (D), and VCAM-1 (E). Administration of dabigatran 15 
attenuated their expression (n = 8–9, per group). (F and G) Flow cytometry analysis 16 
demonstrated that dabigatran decreased ICAM-1 or VCAM-1-positive endothelial cells (n = 17 
6–7, per group). ††; P < 0.01 and †††; P < 0.001 vs. non-diabetic control group, and *; P 18 
< 0.05 and ***; P < 0.001 vs. STZ group. Ctrl; non-diabetic control and Dabi; dabigatran. 19 
All values are mean ± SEM. 20 
 21 
Figure 3. Thrombin promoted pro-inflammatory activation of endothelial cells. 22 
(A) The effect of thrombin on inflammatory molecule expression in HUVEC was examined 23 
by qPCR. Thrombin treatment for 4 hours increased the expression of MCP-1, ICAM-1, and 24 
VCAM-1 in HUVEC (n = 4). (B) The results of western blotting also demonstrated the 25 
increase in ICAM-1 and VCAM-1 expression in thrombin-treated HUVECs in the protein 26 
level (n = 8). (C) The effect of thrombin on the phosphorylation of eNOS and IκBα was 27 
examined by western blotting. Thrombin treatment for 60 minutes decreased eNOS 28 
phosphorylation and increased IκBα phosphorylation (n = 6). (D) Incubation of HUVEC with 29 
thrombin in high glucose condition promotes thrombin-induced expression of ICAM-1 and 30 
MCP-1, suggesting that high glucose condition enhances proinflammatory property of 31 
thrombin (n = 6). *; P < 0.05 and ***; P < 0.001 vs. non-treatment. ††; P < 0.01 and †††; P 32 
< 0.001 vs. thrombin. All values are mean ± SEM. 33 
 34 
Figure 4. NF-κB inhibitor attenuated effects of thrombin on endothelial cells. 35 
(A-C) The effect of a NF-κB inhibitor, BAY11-7082, on thrombin-induced endothelial cell 36 
activation was examined by qPCR. BAY11-7082 inhibited the expression of MCP-1 (A), 37 
ICAM-1 (B), and VCAM-1 (C) which were promoted by thrombin in HUVEC. (D and E) Aortic 38 
segments obtained from wild-type mice were incubated with thrombin in the presence or 39 
absence of a NF-κB inhibitor, BAY11-7082, and then, vascular reactivity to Ach (D) or SNP 40 
(E) was examined. Thrombin significantly inhibited endothelium-dependent vascular 41 
relaxation, while BAY11-7082 attenuated thrombin-induced endothelial dysfunction. 42 
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Neither thrombin nor BAY11-7082 affected endothelium-independent vascular relaxation. 1 
†††; P < 0.001 vs. non-treatment, and *; P < 0.05, **; P < 0.01 and ***; P < 0.001 vs. 2 
thrombin-treatment. NT; non-treatment. All values are mean ± SEM. 3 
  4 
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Table 1. List of PCR primers  
   
 Sense Antisense 
Mouse   
F4/80 5’- TGCATCTAGCAATGGACAGC -3’ 5’- GCCTTCTGGATCCATTTGAA -3’ 
ICAM-1 5’- TTCACACTGAATGCCAGCTC -3’ 5’- GTCTGCTGAGACCCCTCTTG -3’ 
MCP-1 5’- CCACTCACCTGCTGCTACTCAT -3’ 
5’- TGGTGATCCTCTTGTAGCTCTCC -
3’ 
PAR-1 5'- AGAGTCGCTTCCACGAAAGTCCTA -3' 5'- GGTCACAAGCGCGGTGATAA -3' 
PAR-3 5'- TTCTGCCAGTCACTGTTTGC -3' 5'- AGGTTGGCTTTGCTGAGTTG -3' 
PAR-4 5'- GATCCAGCCCTAGACACCCTGA -3' 5'- TGTACCCGCAGGCACATACAA -3' 
VCAM-1 5’- CCCGTCATTGAGGATATTGG -3’ 5’- GGTCATTGTCACAGCACCAC -3’ 
β-actin 5’- CCTGAGCGCAAGTACTCTGTGT -3’ 5’- GCTGATCCACATCTGCTGGAA -3’ 
   
Human   
MCP-1 5’- CCCCAGTCACCTGCTGTTAT -3’ 5’- AGATCTCCTTGGCCACAATG -3’ 
ICAM-1 5’- TGATGGGCAGTCAACAGCTA- 3’ 5’- GGGTAAGGTTCTTGCCCACT -3’ 
VCAM-1 5’- GCTGCTCAGATTGGAGACTCA -3’ 5’- CGCTCAGAGGGCTGTCTATC -3’ 
GAPDH 5’- TGGGTGTGAACCATGAGAAG -3’ 5’- GCTAAGCAGTTGGTGGTGC -3’ 
  1 
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Table2. Effects of dabigatran on metabolic parameters. 
     
 Vehicle 
 (n = 14) 
STZ 
(n = 12) 
STZ+Dabi 
(n = 9) 
P-value 
Body weight, g  21.6±0.6   16.0±0.6***  16.8±0.3*** P<0.001 
Blood glucose, mg/dl  117.6±3.0  528.0±34.9***  533.1±33.0*** P<0.001 
Triglyceride, mg/dl 26.8±3.0 65.2±11.0**  49.8±9.5 P<0.01 
Total cholesterol, mg/dl 62.4±4.3  70.8±9.3  72.4±8.2 NS 
HDL cholesterol, mg/dl 64.4±7.6  82.6±8.3  79.3±10.8 NS 
All values are mean ± SEM. Dabi, dabigatran; HDL, high density lipoprotein. 
**; P < 0.01 and ***; P < 0.001 vs. vehicle  
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